Synthesis and antiviral activities of some 2,3-disubstituted quinazoline derivatives

Article abstract of DOI:10.14233/ajchem.2015.19132

In the search of new leads towards potent antiviral agents 2,3-disubstituted quinazoline derivatives were synthesized and tested for their antiviral activity. Anthranilic acid (1) on treatment with an aromatic acid chloride in pyridine gives 2-aryl-4-oxo-3H-benzoxazines (2) which in turn reacts with p-amino benzoic acid (PABA) to afford 2-aryl-3-p-carboxylatophenyl-4-oxo-3H-quinazolines (3). The compound 3 further reacts with amido alcohols in the presence of conc. H₂SO₄ resulting 3-[benzoic acid-(3-phthalimidomethyl/3-ethyl-3H-2-phenyl- 4-oxo-quinazolinyl/1-ethyl-7-hydroxy-4-methyl-2-oxo-quinolinyl)]-2-aryl-3H-quinazoline-4-ones (4). The resulting compounds 4a-f have been evaluated for their in vitro and in vivo antiviral activity against JEV and HSV type-I. The synthesized compounds were characterized through their physical and chemical analysis. The obtained results can be used as the key step for the building of novel chemical entities with interesting antiviral activity compare with the standard drugs.

Full text of DOI:10.14233/ajchem.2015.19132

Asian Journal of Chemistry; Vol. 27, No. 12 (2015), 4379-4382
A
SIAN
J
OURNAL OF HEMISTRY
C
http://dx.doi.org/10.14233/ajchem.2015.19132
Synthesis and Antiviral Activities of Some 2,3-Disubstituted Quinazoline Derivatives
*
V.D. GUPTA , JOGINDER SINGH, MAYANK KINGER, AVNISH KUMAR ARORA and VIVEK SHEEL JASWAL
Department of Chemistry, Maharishi Markandeshwar University, Mullana, Ambala-133 207, India
*Corresponding author: Fax: +91 1731 274375; Tel: +91 1731 304100; E-mail: vishnugupta442@gmail.com
Received: 26 February 2015;
Accepted: 17 April 2015;
Published online: 29 August 2015;
AJC-17475
In the search of new leads towards potent antiviral agents 2,3-disubstituted quinazoline derivatives were synthesized and tested for their
antiviral activity. Anthranilic acid (1) on treatment with an aromatic acid chloride in pyridine gives 2-aryl-4-oxo-3H-benzoxazines (2)
which in turn reacts with p-amino benzoic acid (PABA) to afford 2-aryl-3-p-carboxylatophenyl-4-oxo-3H-quinazolines (3). The compound
3 further reacts with amido alcohols in the presence of conc. H2SO4 resulting 3-[benzoic acid-(3-phthalimidomethyl/3-ethyl-3H-2-phenyl-
4-oxo-quinazolinyl/1-ethyl-7-hydroxy-4-methyl-2-oxo-quinolinyl)]-2-aryl-3H-quinazoline-4-ones (4). The resulting compounds 4a-f have
been evaluated for their in vitro and in vivo antiviral activity against JEV and HSV type-I. The synthesized compounds were characterized
through their physical and chemical analysis. The obtained results can be used as the key step for the building of novel chemical entities
with interesting antiviral activity compare with the standard drugs.
Keywords: Antiviral activities, 2,3-Disubstituted quinazoline derivatives.
association with varying degree of antiviral activity against
animal and plant viruses10-12. These valid observations led the
authors to undertake the synthesis of 2,3-disubstituted
quinazolones in order to study their antiviral activity against
both, RNA and DNA viruses.
INTRODUCTION
Quinazoline and its derivatives are versatile nitrogen
containing heterocyclic compounds, demonstrating a broad
spectrum of biological and pharmacological activities in animal
as well as in human beings1,2. The chemistry and pharmacology
of quinazolines have been of great interest to medicinal
chemists. Wedding in 1885 synthesized the first quinazolines
and later on, extensive work on this nucleus was done for the
amelioration of human suffering from various diseases and
many drugs incorporating this nucleus were developed. The
designing and devolvement of selective non-nucleoside
inhibitors of virus polymerases is an emerging area of research
activity. Interest in discovering non-nucleoside inhibitor of
virus polymerases increase after the pronounced antiviral
activity of 2-(α-hydroxybenzyl)benzimidazole (HBB) and
methisazone which are truly the selective inhibitors of RNA
polymerase3,4 subsequently other synthetic compounds were
developed and assayed for their antiviral activity. Amongst
various synthetic compounds quinazolines have been demons-
trated to be potential candidate molecules against several
strains of virus since such compound exhibit varying degree
of virus inhibition properties against semliki forest disease
virus (SFV)5, Ranikhet disease virus (RDV)6, Encephalomyo-
carditis virus (EMCV)7, Japanese encephalitis virus (JEV)8
and Herpes simplex virus type-I (HSV-I)9, Interest in quina-
zolones chemistry has increased many folds because of their
EXPERIMENTAL
Melting points of the compounds were determined in open
glass capillaries in the Toshniwal melting points apparatus and
recorded values are uncorrected. IR spectra were recorded in
KBr on Perkin-Elmer 157 spectrophotometer in region νmax
1
4000-400 cm-1 and H NMR and 13C NMR spectra were
recorded on Brooker DRX 200 MHz spectrophotometer using
CDCl3 as solvent (TMS as internal standard with chemical
shift in δ, ppm). Mass spectra were recorded on Hitachi-Elmer
model RMV-7 spectrometer at 70 eV.
Synthesis of 2-aryl-4-oxo-3,1-benzoxazines (2): The
titled compound was prepared according to the method
described in the literature13. Anthranilic acid (0.1 mol) was
dissolved in anhydrous pyridine (50 mL) by stirring slowly at
room temperature. The solution was cooled to 0 °C and an
aromatic acid chloride (0.2 mol) was added drop wise slowly
with constant stirring. After complete addition, the reaction
mixture was further stirred for 0.5 h at room temperature and
kept for 1 h. The dense mass, thus obtained, was diluted with
deionized water (50 mL) and treated with 5 % NaHCO3

4380 Gupta et al.
Asian J. Chem.
solution (50 mL) to remove any unreacted acid. When the
effervescence ceased, it was filtered off and washed with
deionized water in order to remove the adhered pyridine and
inorganic materials. The crude benzoxazines thus prepared,
were dried and recrystallized using dilute ethanol.
2-Phenyl-3-(hydroxyethyl)-4-(3H)-quinazolone: m.p.:
164-165 °C.Yield 80 % (Found: N, 10.55 % C16H14N2O2 requires
N, 10.53 %)
2-Styryl-3-(hydroxyethyl)-4-(3H)-quinazolone: m.p.:
108-109 °C.Yield 75 % (Found: N, 9.54 % C18H16N2O2 requires
N, 9.58 %)
1-Hydroxyethyl-7-hydroxy-4-methyl-2-oxo-quinoline:
m.p.: 172-173 °C. Yield 75 % (Found: N, 6.10 % C12H13NO2
requires N, 6.39 %)
Preparation of 3-[benzoic acid-(3-phthalimido methyl/
3-ethyl-3H-2-phenyl-4-oxo-quinazolinyl/1-ethyl-7-hydroxy-
4-methyl-2-oxo-quinolinyl)]-2-aryl-3H-quinazoline-4-ones
(4a-f): The method of Tscherniac17 was followed for amido
alkylation of compound 3. A mixture of compound 3 and N-
hydroxy methyl phthalimide/2-aryl-3-(ethanoic acid)-4-(3H)-
quinazoline/1-ethanoic acid-7-hydroxy-methyl-2-oxo-quino-
line (0.01 mol) was dissolved in minimum quantity of conc.
H2SO4 in cold conditions and stirred for 1 h then left overnight.
A solid is separated out after pouring the content in ice cold
water, which is filtered off and washed with water to remove
sulphonated products.After drying under vacuum it is recrysta-
llized from ethanol (Scheme-I).
2-Phenyl-4-oxo-3,1-benzoxazines: m.p.: 122-123 °C.
Yield 75 % (Found: N, 6.11 %: C14H9NO2 requires N, 6.27 %).
2-Styryl-4-oxo-3,1-benzoxazines: m.p.: 209-210 °C.
Yield 60 % (Found: N, 5.56 %: C16H11NO2 requires N, 5.62 %).
Synthesis of 2-aryl-3-p-carboxylatophenyl-4-oxo-3H-
quinazolines (3) The compound 3 was prepared according to
the method described in the literature14. A mixture of 2-aryl-
4-oxo-3,1-benzoxazines (0.05 mol) (2) and p-amino benzoic
acid (0.05 mol) in dry pyridine (50 mL) was heated under
reflux for 6 h under anhydrous reaction conditions and then
allowed to cool at room temperature. The reaction mixture
was then treated with dilute hydrochloric acid (5 mL) and
stirred. The solid thus separated was filtered off and washed
with deionized water to remove pyridine. The crude quinazolones
was dried under vacuum and recrystallized from dilute ethanol.
2-Phenyl-3-benzoic acid)-4-(3H)-quinazolones: m.p.:
199-200 °C. Yield 65 % (Found: N, 8.75 %: C21H14N2O3
requires N, 8.91 %).
COOH
O
2-Styryl-3-(4-benzoic acid)-4-(3H)-quinazolones: m.p.:
159-160 °C. Yield 61 % (Found: N, 8.55 %: C23H16N2O3
requires N, 8.23 %).
O
NH2
RCOCl
PABA
O
N
Pyridine
Pyridine
COOH
N
R
N
R
Synthesis of N-hydroxymethyl phthalimide: The titled
compound was prepared according to the method described
in the literature15.A mixture of phthalimide (0.1 mol), formalin
(0.25 mol) and anhydrous potassium carbonate (1 g) was
dissolved in water (50 mL) by heating on a water bath for
5 min. The resultant solution was stirred for 15 min and then
refluxed on a sand-bath for 2 h. On cooling, a solid separated
out which was filtered off and washed repeatedly with ice-cold
water. The solid thus obtained, was dried and recrystallized
from ethanol. A colorless needle was obtained. m.p., 149-
150 °C, Yield-75 %.
Synthesis of 7-hydroxy-4-methyl coumarin: The titled
compound was prepared according to the method described
in the literature16. A mixture of resorcinol (5.5 g) and ethyl
acetoacetate (6.35 mL) with 75 % H2SO4 (50 mL) in a 100 mL
conical flask heated on the water bath at 100 °C for 0.5 h.
Cool the resulting dark green solution and stir in to crushed
ice. Filter off the crud product and wash with water to remove
impurities and recrystallized from methanol. A pale yellow
plate was obtained. m.p. 185-186 °C, Yield 85 %.
Synthesis of 2-aryl-3-(hydroxyl ethyl)-4-(3H)-quinazo-
line/1-hydroxyethyl-7-hydroxy-4-methyl-2-oxo-quinoline:
The titled compound was prepared according to the method
described in the literature17. A mixture of 2-aryl-4-oxo-3,1-
benzoxazines (2) (0.05 mol)/7-hydroxy-4-methyl coumarin
(0.05 mol) was dissolved in dry pyridine (50 mL) and stirred
vigorously followed by adding β-aminoethenol (0.05 mL) in
portion with constant shaking. Subsequently reaction mixture
was refluxed for 6 h and then allowed to cool, which is treated
with dilute hydrochloric acid. The solid separated out was
filtered off washed with water and dried over silica gel. It is
recrystallized from ethanol.
1
2
3
R'OH
H2SO4
COOH
R'
O
N
R
N
4a-4f
Compound No.
R
R'
O
4a
Phenyl
Styryl
NCH2
O
O
4b
NCH2
O
O
NCH2
4c
Phenyl
Styryl
N
O
NCH2
CH3
4d
N
4e
4f
Phenyl
Styryl
HO
N
O
O
CH2
CH3
HO
N
CH2
Scheme-I

Vol. 27, No. 12 (2015)
Synthesis and Antiviral Activities of Some 2,3-Disubstituted Quinazoline Derivatives 4381
3-[Benzoic acid-(3-phthalimido methyl)]-2-phenyl-3H-
quinazoli-ne-4-ones (4a): IR (KBr) (νmax in cm-1): 1610 (C=N
str.), 1686 (Ph-N-C=O str.), 1755 (CH2-N=C=O str.), 3000
(Phenolic- COOH str.); 1H NMR (δ, ppm) (CDCl3): 4.89 (m,
2H), 7.29-7.99 (m, 16H, Ar-H), 11.0 (s, 1H, OH); 13C NMR
(δ, ppm) (CDCl3): 35.8, 119.1, 119.5, 120.9, 122.4, 124.0,
126.1, 127.4, 127.6, 128.7, 128.8, 128.9, 130.2, 130.3, 132.1,
132.3, 132.5, 133.5, 137.8, 138.3, 151.3, 160.9, 164.0, 168.2
& 169.4; Mass (m/z): 456, 445, 313, 247, 145, 119, 105 (base
peak), 396 and 376.
3-[Benzoic acid-(3-phthalimido methyl)]-2-styryl-3H-
quinazolin e-4-ones (4b): IR (KBr) (vmax in cm-1): 1610 (C=N
str.), 1686 (Ph-N-C=O str.), 1755 (CH2-N=C=O str.), 3000
(Ar -COOH str.); 1H NMR (δ, ppm) (CDCl3): 4.89 (m, 2H),
7.29-7.99 (m, 16H, Ar-H), 11.0 (s, 1H, OH); 13C NMR (δ,
ppm) (CDCl3): 35.8, 112.0, 119.1, 119.5, 120.9, 122.4, 124.0,
126.1, 127.4, 127.6, 128.7, 128.8, 128.9, 130.2, 130.3, 132.1,
132.3, 132.5, 133.5, 137.8, 138.3, 151.3, 160.9, 164.0, 168.2
& 169.4; Mass (m/z): 456, 445, 313, 247, 145, 119, 105 (base
peak), 396 and 376.
3-[Benzoic acid-(3-ethyl-3H-4-oxo-quinazolinyl)]-2-
phenyl-3H-quinazoline-4-ones (4c): IR (KBr) (vmax in cm-1):
1610 (C=N str.), 1686 (Ph-N-C=O str.), 1755 (CH2-N=C=O
str.), 3000 (Ar -COOH str.); 1H NMR (δ, ppm) (CDCl3): 4.46
(m, 2H), 7.29-7.99 (m, 16H,Ar-H), 11.0 (s, 1H, OH); 13C NMR
(δ, ppm) (CDCl3): 38.6, 119.1, 119.5, 120.9, 122.4, 127.4,
128.7, 128.8, 128.9, 130.2, 130.3, 133.5, 137.8, 138.3, 147.1,
147.5, 151.3, 160.9, 164.0, & 169.4; Mass (m/z): 456, 445,
313, 247, 145, 119, 105 (base peak), 396 and 376.
3-[Benzoic acid-(3-ethyl-3H-4-oxo-quinazolinyl)]-2-
styryl-3H-quinazoline-4-ones (4d): IR (KBr) (vmax in cm-1):
1610 (C=N str.), 1686 (Ph-N-C=O str.), 1755 (CH2-N=C=O
str.), 3000 (Ar -COOH str.); 1H NMR (δ, ppm) (CDCl3): 4.46
(m, 2H), 7.29-7.99 (m, 16H,Ar-H), 11.0 (s, 1H, OH); 13C NMR
(δ, ppm) (CDCl3): 38.6, 112.0, 119.1, 119.5, 120.9, 122.4,
127.4, 128.7, 128.8, 128.9, 130.2, 130.3, 133.5, 137.8, 138.3,
147.1, 147.5, 151.3, 160.9, 164.0, & 169.4; Mass (m/z): 456,
445, 313, 247, 145, 119, 105 (base peak), 396 and 376.
3-[Benzoic acid-(1-ethyl-7-hydroxy-4-methyl-2-oxo-
quinolinyl)]-2-phenyl-3H-quinazoline-4-ones (4e): IR (KBr)
(vmax in cm-1): 1610 (C=N str.), 1686 (Ph-N-C=O str.), 1755
(CH2-N=C=O str.), 3000 (Ar -COOH str.); 1H NMR (δ, ppm)
(CDCl3): 1.71 (s, 3H), 4.22 (m, 2H), 5.0 (s, 1H, OH), 6.35 (q,
1H), 7.06-7.99 (m, 15H, Ar-H), 11.0 (s, 1H, OH); 13C NMR
(δ, ppm) (CDCl3): 20.8, 38.2, 41.5, 61.6, 106.3, 111.4, 119.4,
119.8, 120.7, 120.9, 122.2, 122.4, 126.4, 127.4, 128.0, 128.7,
128.8, 131.5, 133.5, 135.2, 135.8, 136.7, 138.2, 139.0, 147.1,
148.8, 157.9, 160.9, 161.8 & 164.0; Mass (m/z): 456, 445,
313, 247, 145, 119, 105 (base peak), 396 and 376.
3-[Benzoic acid-(1-ethyl-7-hydroxy-4-methyl-2-oxo-
quinolinyl)]-2-styryl-3H-quinazoline-4-ones (4f): IR (KBr)
(vmax in cm-1): 1610 (C=N str.), 1686 (Ph-N-C=O str.), 1755
(CH2-N=C=O str.), 3000 (Ar -COOH str.); 1H NMR (δ, ppm)
(CDCl3): 1.71 (s, 3H), 4.22 (m, 2H), 5.0 (s, 1H, OH), 5.6 (m,
1H), 6.6 (m, 1H), 7.06-7.99 (m, 16H, Ar-H), 11.0 (s, 1H, OH);
13C NMR (δ, ppm) (CDCl3): 20.8, 38.2, 41.5, 61.6, 106.3,
111.4, 112.0, 119.4, 119.8, 120.7, 120.9, 122.2, 122.4, 126.4,
127.4, 128.0, 128.7, 128.8, 131.5, 133.5, 135.2, 135.8, 136.7,
138.2, 139.0, 147.1, 148.8, 157.9, 160.9 & 161.8; Mass (m/z):
456, 445, 313, 247, 145, 119, 105 (base peak), 396 and 376.
Antiviral activity: All the six synthesized compounds
(4a-f) were evaluated for their antiviral activity against two
animal viruses viz., JEV (P20778) and HSV-I (753166)
originally obtained from National Institute of Virology Pune
(India). Antiviral activity was performed in vitro (Vero cells)
and in vivo (Swiss-albino-mico). Both the viruses were
maintained by introcerebral passages of 1-3 days old suckling
Swiss albino-mice. Vero cell were maintained in minimum
essential medium (MEM) (Sigma, USA) with 10 % foetal
bovine serum (FBS) (Gibco, USA) and 100 units of penicillin
100 µg of streptomycin and 40 µg mL-1 of gentamycin were
added. Cytotoxicity as well as antiviral assay of the compounds
was performed in 96 well µL plates (non-clone Denmark) by
the standard method. For in vivo testing the treated and
untreated mice were observed for 21 days post infection. Upon
the termination of experiment the percent protection and the
mean survival time (MST) in day were calculated.
RESULTS AND DISCUSSION
The method of Tscherniac17 was followed for the synthesis
of 3-[benzoic acid-(3-phthalimido methyl/3-ethyl-3H-2-
phenyl-4-oxo-quinazolinyl/1-ethyl-7-hydroxy-4-methyl-2-
oxo-quinolinyl)]-2-aryl-3H-quinazoline-4-ones (4a-f). The
synthesized compounds were characterized by elemental
1
analysis, FTIR, H NMR, 13C NMR and mass spectral data
(Table-1).
All the compounds (4a-f) investigated for their anti-JEV
and anti-HSV-I activity (Tables 2 and 3), were found active
both in vitro and in vivo studies. The maximum percentage
inhibition was 55 % in in vivo studies as compared to in vitro
studies for anti-JEV activity and on the other hand the
maximum percentage inhibition was 56 % in in vitro studies
for anti-HSV-1 activity.
TABLE-1
PHYSICAL AND ANALYTICAL DATA OF 3-[BENZOIC ACID-(3-PHTHALIMIDO METHYL/3-ETHYL-3H-2-PHENYL-4-OXO-
QUINAZOLINYL/1-ETHYL-7-HYDROXY-4-METHYL-2-OXO-QUINOLINYL)]-2-ARYL-3H-QUINAZOLINE-4-ONES (4a-f)
N (%)
Comp.
No.
R
R'
m.p. (°C)
Yield (%)
m.f.
Found
8.82
8.83
9.93
9.49
8.10
8.09
Calcd.
8.87
8.41
9.96
9.52
8.15
8.12
Phenyl
Styryl
Phenyl
Styryl
Phenyl
Styryl
Phthalimido methyl
Phthalimido methyl
120-122
160-164
135-140
158-160
139-141
162-164
75
70
65
65
61
55
C30H19N3O5
C32H21N3O5
C37H26N4O4
C39H28N4O4
C33H25N3O5
C35H27N3O5
4a
4b
4c
4d
4e
4f
3-Ethyl-3H-2-phenyl-4-oxo-quinazolinyl
3-Ethyl-3-2-phenyl-4-oxo-quinazolinyl
1-Ethyl-7-hedroxy-4-methyl-2-oxo-quinazolinyl
1-Ethyl-7-hydroxy-4-methyl-2-oxo-quinazolinyl

4382 Gupta et al.
Asian J. Chem.
TABLE-2
ANTI-JEV ACTIVITY DATA OF 3-[BENZOIC ACID-(3-PHTHALIMIDO METHYL/3-ETHYL-3H-2-PHENYL-4-OXO-QUINAZOLINYL/
1-ETHYL-7-HYDROXY-4-METHYL-2-OXO-QUINOLINYL)]-2-ARYL-3H-QUINAZOL-INE-4-ONES (4a-f)
in vitro
in vivo
Dose (µg/
mouse/day)
CPE
inhibition
(%)
Compd.
No.
Protection
(%)
R
R'
TI
Dose
CT50
EL50
MST
(days)
(µg/mL) (µg/mL) (µg/mL)
Phenyl Phthalimidomethyl
Styryl Phthalimidomethyl
Phenyl 3-Ethyl-3H-2-phenyl-4-oxo-
500-4
500-4
500-4
500
500
500
125
100
125
04
05
04
40
50
40
200
200
200
7
4
7
55
40
35
4a
4b
4c
quinazolinyl
Styryl
3-Ethyl-3-2-phenyl-4-oxo-
quinazolinyl
500-4
500-4
500-4
500
500
500
100
125
100
05
04
05
50
40
50
200
200
200
4
7
4
42
30
40
4d
4e
4f
Phenyl 1-Ethyl-7-hedroxy-4-
methyl-2-oxo-quinazolinyl
Styryl
1-Ethyl-7-hydroxy-4-
methyl-2-oxo-quinazolinyl
CT50= 50 % cytotoxic concentration; EC50 = 50 % effective concentration; TI = Therapeutic index; CPE = Cytopathic effect; MST = Mean survival
time.
TABLE-3
ANTI-HSV-I ACTIVITY DATA OF 3-[BENZOIC ACID-(3-PHTHALIMIDO METHYL/3-ETHYL-3H-2-PHENYL-4-OXO-
QUINAZOLINYL/1-ETHYL-7-HYDROXY-4-METHYL-2-OXO-QUINOLINYL)]-2-ARYL-3H-QUINAZOL-INE-4-ONES (4a-4f)
in vitro
in vivo
Dose (µg/
mouse/day)
CPE
inhibition
(%)
Compd.
No.
Protection
(%)
R
R'
TI
Dose
CT50
EL50
MST
(days)
(µg/mL) (µg/mL) (µg/mL)
Phenyl Phthalimidomethyl
Styryl Phthalimidomethyl
Phenyl 3-Ethyl-3H-2-phenyl-4-oxo-
500-4
500-4
500-4
250
250
250
7.8
15.62
7.8
32
16
32
45
26
55
200
200
200
7
4
7
40
20
10
4a
4b
4c
quinazolinyl
Styryl
3-Ethyl-3-2-phenyl-4-oxo-
quinazolinyl
500-4
500-4
500-4
250
250
250
62.5
62.5
125
04
04
02
55
56
20
200
200
200
4
7
4
10
20
30
4d
4e
4f
Phenyl 1-Ethyl-7-hedroxy-4-
methyl-2-oxo-quinazolinyl
Styryl
1-Ethyl-7-hydroxy-4-
methyl-2-oxo-quinazolinyl
CT50= 50 % cytotoxic concentration; EC50= 50 % effective concentration; TI= Therapeutic index; CPE= Cytopathic effect; MST= Mean survival
time.
2. V.K. Tandon, D.B. Yadav, H.K. Maurya, A.K. Chaturvedi and P.K.
Conclusion
Shukla, Bioorg. Med. Chem., 14, 6120 (2006).
In present study, the synthesis of 3-[benzoic acid-(3-
phthalimido methyl/3-ethyl-3H-2-phenyl-4-oxo-quinazolinyl/
1-ethyl-7-hydroxy-4-methyl-2-oxo-quinolinyl)]-2-aryl-3H-
quinazoline-4-ones (4a-f) is described. The structures of the
synthesized compounds were confirmed and characterized by
elemental analysis and spectral studies. It was observed that
some of the synthesized compounds showed excellent anti-
JEV and anti-HSV-I activities.
3. D. Hamre, J. Bernstein and R. Donovick, Proc. Soc. Exp. Biol. Med.,
73, 275 (1950).
4. I. Tamm, H.J. Eggers, R. Bablanian, A.F. Wagner and K. Folkers, Nature,
223, 785 (1969).
5. V.K. Pandey and A.K. Aggarwal, Indian J. Chem., 14, 27 (1980).
6. V.K. Pandey, D. Mishra and A. Shukla, Indian Drugs, 31, 532 (1994).
7. V.K. Pandey, D. Misra, M.N. Joshi and K. Chandra, Pharmacol. Res.
Commun., 20, 153 (1988).
8. V.K. Pandey and H.S. Negi, Indian J. Chem., 42B, 206 (2003).
9. V.K. Pandey and A. Shukla, Indian J. Chem., 38B, 1381 (1999).
10. V.K. Pandey, K.C. Khulbe, G. Saxena, P. Gupta and K. Chandra, Indian
Drugs, 30, 513 (1993).
ACKNOWLEDGEMENTS
11. V.K. Pandey, A.K. Aggarwal, B.M. Gupta and S.K. Raj, Biol. Memoirs,
9, 197 (1984).
12. V.K. Pandey and H.S. Negi, Biol. Memoirs, 25, 29 (1999).
13. N.W. Hirwe and K.N. Rana, Chem. Ber., 72, 1346 (1939).
14. V.K. Pandey and L.P. Pathak, Indian J. Chem., 44B, 1940 (2005).
15. S.R. Buc, J. Am. Chem. Soc., 69, 254 (1947).
The authors thanks to The Head, Chemistry Department,
Maharishi Markandeshwar University, Mullana-Ambala, India
for providing necessary laboratory facilities and also to the
Head of Chemistry Department, Punjab University, Chandigarh,
India for elemental analysis and spectral data.
16. H. von Pechmann and C. Duisberg, Berichte, 16, 19 (1833).
17. J. Tschermiac, German Patent, 134979; Chem. Abstr., vol. 2, 1084 (1902).
REFERENCES
1. A.K. Patidar, M. Jeyakandan, A.K. Mobiya and G. Selvam, Int. J.
Pharm. Tech. Res., 3, 386 (2011).